Recent results from large phase II/III clinical trials on adenoviral-mediated VEGF delivery have been inconclusive if not disappointing so far. We believe a sounder strategy may be to take advantage of the HIF-11 upstream transcriptional regulator that can activate several downstream genes such as VEGF, FGF, IGF, angiopoietin, and erythropoietin. However, HIF-11 has a short biological half-life due to endogenous degradation by prolyl hydroxylase-2 (PHD2). Therefore, we hypothesize that short hairpin inhibition of PHD2 (shPHD2) represent a novel approach to induce therapeutic angiogenesis. On the flip side, persistent and unregulated angiogenesis can lead to hemangioma in the heart and thus controlling gene expression in a targeted and regulatory fashion is needed. Another priority is to develop novel techniques that can be used to track gene expression in living subjects noninvasively, longitudinally, and quantitatively. Thus, the primary goal of this R01 proposal is to use our multi-disciplinary expertise in vector design, molecular imaging, vascular biology, and translational models to address the above questions.
Our specific aims are to (1) develop smart vectors with robust and prolonged transgene expression, (2) monitor the pharmacokinetics and biodistribution of our novel vector in vivo, (3) demonstrate mechanisms of shPHD2 mediated gene therapy for myocardial ischemia, and (4) evaluate the safety, efficacy, and optimal delivery conditions in translational models. At the end of 5 years, we hope to translate these findings to treatment of coronary artery disease patients with our novel smart vector systems.

Public Health Relevance

Although initial phase 1 trials in patients with myocardial ischemia provided encouraging results, recent phase 2 randomized trials (AGENT, VIVA, KAT) yielded only modest benefits. These inconsistencies have been attributed to lack of ideal delivery vectors, unclear role of single therapeutic gene such as VEGF, suboptimal dosing or route of administration, and inability to monitor gene transfer in patients. For the field to move forward, the pressing questions that need to be resolved are: (i) finding a suitable vector to overcome physical barriers, (ii) develop a novel method mean to verify gene expression in vivo, (iii) dissect the molecular mechanisms of gene therapy, and (iv) demonstrate safety and efficacy in translational models. The significance of this R01 proposal is to validate that chemical conjugation can be used to significantly improve the transfection efficiency of plasmid DNA, that novel molecular imaging platforms will allow us to monitor the pharmacokinetics and biodistribution of gene therapy in living subjects, that a """"""""smart vector system"""""""" can be designed to be tissue specific and hypoxia responsive, and finally that gene therapy can be used in small animals, large animals, and human subjects in the future.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL093172-02
Application #
7807018
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Danthi, Narasimhan
Project Start
2009-04-15
Project End
2014-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
2
Fiscal Year
2010
Total Cost
$411,908
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Nguyen, Patricia K; Wu, Joseph C (2015) Large Animal Models of Ischemic Cardiomyopathy: Are They Enough to Bridge the Translational Gap? J Nucl Cardiol 22:666-72
Ong, Sang-Ging; Lee, Won Hee; Kodo, Kazuki et al. (2015) MicroRNA-mediated regulation of differentiation and trans-differentiation in stem cells. Adv Drug Deliv Rev 88:3-15
Ong, Sang-Ging; Wu, Joseph C (2015) Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration. Circ Res 117:7-9
Nguyen, Patricia K; Lee, Won Hee; Li, Yong Fuga et al. (2015) Assessment of the Radiation Effects of Cardiac CT Angiography Using Protein and Genetic Biomarkers. JACC Cardiovasc Imaging 8:873-84
Dash, Rajesh; Kim, Paul J; Matsuura, Yuka et al. (2015) Manganese-Enhanced Magnetic Resonance Imaging Enables In Vivo Confirmation of Peri-Infarct Restoration Following Stem Cell Therapy in a Porcine Ischemia-Reperfusion Model. J Am Heart Assoc 4:
Lee, Won Hee; Nguyen, Patricia; Hu, Shijun et al. (2015) Variable activation of the DNA damage response pathways in patients undergoing single-photon emission computed tomography myocardial perfusion imaging. Circ Cardiovasc Imaging 8:e002851
Pavo, Noemi; Emmert, Maximilian Y; Giricz, Zoltán et al. (2014) On-line visualization of ischemic burden during repetitive ischemia/reperfusion. JACC Cardiovasc Imaging 7:956-8
Cheng, Kai; Kothapalli, Sri-Rajasekhar; Liu, Hongguang et al. (2014) Construction and validation of nano gold tripods for molecular imaging of living subjects. J Am Chem Soc 136:3560-71
Chen, Heidi I; Poduri, Aruna; Numi, Harri et al. (2014) VEGF-C and aortic cardiomyocytes guide coronary artery stem development. J Clin Invest 124:4899-914
Ong, Sang-Ging; Lee, Won Hee; Huang, Mei et al. (2014) Cross talk of combined gene and cell therapy in ischemic heart disease: role of exosomal microRNA transfer. Circulation 130:S60-9

Showing the most recent 10 out of 41 publications